Amino Acid Polymorphisms in Hla Class II Differentiate Between Thyroid and Polyglandular Autoimmunity

Area of Science:

• Immunogenetics
• Molecular immunology
• Autoimmune disease research

Background:

• The structure of human leucocyte antigen (HLA) peptide-binding clefts is crucial in determining susceptibility to monoglandular and polyglandular autoimmunity (AP).
• Understanding the role of specific amino acid polymorphisms in HLA class II molecules is essential for elucidating the mechanisms underlying AP.

Purpose of the Study:

• To investigate the impact of amino acid polymorphisms within HLA class II peptide-binding interactions.
• To determine the association of these polymorphisms with the risk of developing polyglandular autoimmunity (AP).

Main Methods:

• An immunogenetic study involving 587 subjects with AP, autoimmune thyroid disease (AITD), type 1 diabetes (T1D), and healthy controls.
• HLA class II typing was performed, and amino acids within the peptide binding cleft encoded by HLA class II exon 2 were analyzed.
• Statistical analysis included Monte Carlo exact Fisher tests to compare allele distributions and identify significant amino acid positions.

Main Results:

• Significant differences in HLA class II loci (DQA1, DQB1, DRB1) were observed between AP and AITD/controls, and between different subtypes of AP.
• Seven specific amino acid positions (DRB1-13, DRB1-26, DRB1-71, DRB1-74, DQA1-47, DQA1-56, DQB1-57) were found to significantly contribute to AP.
• Five positions in DQA1 (11, 47, 50, 56, and 69) showed complete correlation with AP.

Conclusions:

• Amino acid polymorphisms within HLA class II exon 2 play a critical role in mediating the risk of polyglandular autoimmunity (AP).
• These specific HLA polymorphisms can differentiate between the risk profiles for autoimmune thyroid disease and polyglandular autoimmunity.